![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 31-Jan-2012[ | E-mail |
Share ] Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
New research in the FASEB Journal describes a novel antibody that blocks inflammation that leads to transplant rejection: 'Toll-like' receptors are its target
New research published online in the FASEB Journal (http://www.fasebj.org) details a new antibody, called "OPN-305" that may significantly improve survival outcomes for those receiving donated kidneys and other organs. OPN-305 works by preventing inflammation triggered by oxygen deprivation in the donated organ, allowing for better recovery after transplantation. Specifically, it binds to sensors on transplant tissue, called "toll-like receptors" or "TLR-2," in the circulating blood and turns off signals that provoke inflammation. In addition, the compound is likely to extend the life of a donated organ after it has been transplanted.
"Although the work was carried out with kidney transplants, it is likely that other types of transplants could benefit. Other common types of organ transplants, needed for liver or heart or lung disease, are also vulnerable to damage induced by the transplant procedure, especially where there has been a long period of cold storage without a normal blood supply," said Steven H. Sacks, study author from the MRC Centre for Transplantation at King's College School of Medicine in London. "For other medical conditions such as stroke and heart attack, where the blood flow to vital organs is blocked, it is highly possible that this new treatment may also make recovery more complete."
Sacks and colleagues made this discovery using two groups of mice receiving kidney transplants. The first was treated with OPN-305 and the second was given an irrelevant agent. The group treated with the OPN-305 showed good recovery of function in the transplanted organ, whereas the control treatment had no effect and the animals developed severe organ damage. Researchers say a clinical trial design using a similar antibody for use in human patients is underway.
"This new antibody is exciting because it basically increases the 'shelf life' of organs that are critically needed for transplantation," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal. "Since it is directed against molecules that regulate inflammation, OPN-305 is likely to extend the lifespan of any other transplanted organs. Although human trials have not yet begun, this work identifies TLR's as targets for drugs to reduce inflammation and organ rejection."
###
Receive monthly highlights from the FASEB Journal by e-mail. Sign up at http://www.faseb.org/fjupdate.aspx. The FASEB Journal (http://www.fasebj.org) is published by the Federation of the American Societies for Experimental Biology (FASEB) and is the most cited biology journal worldwide according to the Institute for Scientific Information. In 2010, the journal was recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century. FASEB comprises 26 societies with more than 100,000 members, making it the largest coalition of biomedical research associations in the United States. Celebrating 100 Years of Advancing the Life Sciences in 2012, FASEB is rededicating its efforts to advance health and well-being by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 31-Jan-2012[ | E-mail |
Share ] Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
New research in the FASEB Journal describes a novel antibody that blocks inflammation that leads to transplant rejection: 'Toll-like' receptors are its target
New research published online in the FASEB Journal (http://www.fasebj.org) details a new antibody, called "OPN-305" that may significantly improve survival outcomes for those receiving donated kidneys and other organs. OPN-305 works by preventing inflammation triggered by oxygen deprivation in the donated organ, allowing for better recovery after transplantation. Specifically, it binds to sensors on transplant tissue, called "toll-like receptors" or "TLR-2," in the circulating blood and turns off signals that provoke inflammation. In addition, the compound is likely to extend the life of a donated organ after it has been transplanted.
"Although the work was carried out with kidney transplants, it is likely that other types of transplants could benefit. Other common types of organ transplants, needed for liver or heart or lung disease, are also vulnerable to damage induced by the transplant procedure, especially where there has been a long period of cold storage without a normal blood supply," said Steven H. Sacks, study author from the MRC Centre for Transplantation at King's College School of Medicine in London. "For other medical conditions such as stroke and heart attack, where the blood flow to vital organs is blocked, it is highly possible that this new treatment may also make recovery more complete."
Sacks and colleagues made this discovery using two groups of mice receiving kidney transplants. The first was treated with OPN-305 and the second was given an irrelevant agent. The group treated with the OPN-305 showed good recovery of function in the transplanted organ, whereas the control treatment had no effect and the animals developed severe organ damage. Researchers say a clinical trial design using a similar antibody for use in human patients is underway.
"This new antibody is exciting because it basically increases the 'shelf life' of organs that are critically needed for transplantation," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal. "Since it is directed against molecules that regulate inflammation, OPN-305 is likely to extend the lifespan of any other transplanted organs. Although human trials have not yet begun, this work identifies TLR's as targets for drugs to reduce inflammation and organ rejection."
###
Receive monthly highlights from the FASEB Journal by e-mail. Sign up at http://www.faseb.org/fjupdate.aspx. The FASEB Journal (http://www.fasebj.org) is published by the Federation of the American Societies for Experimental Biology (FASEB) and is the most cited biology journal worldwide according to the Institute for Scientific Information. In 2010, the journal was recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century. FASEB comprises 26 societies with more than 100,000 members, making it the largest coalition of biomedical research associations in the United States. Celebrating 100 Years of Advancing the Life Sciences in 2012, FASEB is rededicating its efforts to advance health and well-being by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2012-01/foas-nai013112.php
makana gloria cain gloria cain kandi burruss occupy portland occupy portland the hunger games
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.